Company intelligence / Profile preview

ExoRNA Bioscience

Shenzhen*, Guangdong Sheng, Chinaorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company’s lead asset, ER‑2001, is in Phase 1 trials for Huntington Disease to evaluate safety, tolerability, pharmacokinetics/dynamics, and early efficacy signals using an intravenous exosome-based siRNA approach targeting LAMP‑2. No published efficacy results yet; trial ongoing/recruiting as of April 2025

Therapeutic areas: Neurology
Modalities: siRNA (small interfering RNA)Nucleic acid drugs delivered via exosome platform
Industry: Biotech

Drug pipeline

1 asset

ER2001

Beyond the preview

Go deeper on ExoRNA Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoRNA Bioscience.

Explore the full profile